Cargando…
Case Report: Management of Primary Tracheobronchial Light Chain Amyloidosis in a Patient With Biclonal Gammopathy Using a Systemic Bortezomib-Based Regimen
Primary tracheobronchial light chain (AL) amyloidosis is a rare and heterogeneous disease characterized by the buildup of amyloid deposits in the airway mucosa. Although its treatment remains challenging, the current view is that the localized form can be treated conservatively due to its slow progr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554224/ https://www.ncbi.nlm.nih.gov/pubmed/34722570 http://dx.doi.org/10.3389/fmed.2021.728561 |
_version_ | 1784591749703794688 |
---|---|
author | Yan, Wei Li, Peng Wu, Cen Zhou, Chuming Liao, Aijun Yang, Wei Wang, Huihan |
author_facet | Yan, Wei Li, Peng Wu, Cen Zhou, Chuming Liao, Aijun Yang, Wei Wang, Huihan |
author_sort | Yan, Wei |
collection | PubMed |
description | Primary tracheobronchial light chain (AL) amyloidosis is a rare and heterogeneous disease characterized by the buildup of amyloid deposits in the airway mucosa. Although its treatment remains challenging, the current view is that the localized form can be treated conservatively due to its slow progression. While radiotherapy has proven effective in treating localized form of the disease, some patients do not respond to local treatment and continue to experience poor quality of life, highlighting the need to explore additional treatment strategies. In this report, we discuss a case of primary tracheobronchial AL amyloidosis with biclonal gammopathy (IgA κ and IgG κ) in a 46-year-old man who was transferred to our hospital due to dyspnea progression over the preceding 3 years. Chest computed tomography revealed irregular tracheobronchial stenosis with wall thickening, and histological examination of the bronchial biopsies confirmed the diagnosis of endobronchial AL amyloidosis. Owing to the poor effect of radiation therapy and treatments for improving airway patency, he was treated with a systemic chemotherapy regimen [cyclophosphamide-bortezomib-dexamethasone (CyBorD)]. We observed substantial improvements in his dyspnea, highlighting the potential of systemic therapy to improve quality of life of patients with tracheobronchial AL amyloidosis. However, the long-term pathological changes associated with local bronchial lesions require further investigation. |
format | Online Article Text |
id | pubmed-8554224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85542242021-10-30 Case Report: Management of Primary Tracheobronchial Light Chain Amyloidosis in a Patient With Biclonal Gammopathy Using a Systemic Bortezomib-Based Regimen Yan, Wei Li, Peng Wu, Cen Zhou, Chuming Liao, Aijun Yang, Wei Wang, Huihan Front Med (Lausanne) Medicine Primary tracheobronchial light chain (AL) amyloidosis is a rare and heterogeneous disease characterized by the buildup of amyloid deposits in the airway mucosa. Although its treatment remains challenging, the current view is that the localized form can be treated conservatively due to its slow progression. While radiotherapy has proven effective in treating localized form of the disease, some patients do not respond to local treatment and continue to experience poor quality of life, highlighting the need to explore additional treatment strategies. In this report, we discuss a case of primary tracheobronchial AL amyloidosis with biclonal gammopathy (IgA κ and IgG κ) in a 46-year-old man who was transferred to our hospital due to dyspnea progression over the preceding 3 years. Chest computed tomography revealed irregular tracheobronchial stenosis with wall thickening, and histological examination of the bronchial biopsies confirmed the diagnosis of endobronchial AL amyloidosis. Owing to the poor effect of radiation therapy and treatments for improving airway patency, he was treated with a systemic chemotherapy regimen [cyclophosphamide-bortezomib-dexamethasone (CyBorD)]. We observed substantial improvements in his dyspnea, highlighting the potential of systemic therapy to improve quality of life of patients with tracheobronchial AL amyloidosis. However, the long-term pathological changes associated with local bronchial lesions require further investigation. Frontiers Media S.A. 2021-10-15 /pmc/articles/PMC8554224/ /pubmed/34722570 http://dx.doi.org/10.3389/fmed.2021.728561 Text en Copyright © 2021 Yan, Li, Wu, Zhou, Liao, Yang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Yan, Wei Li, Peng Wu, Cen Zhou, Chuming Liao, Aijun Yang, Wei Wang, Huihan Case Report: Management of Primary Tracheobronchial Light Chain Amyloidosis in a Patient With Biclonal Gammopathy Using a Systemic Bortezomib-Based Regimen |
title | Case Report: Management of Primary Tracheobronchial Light Chain Amyloidosis in a Patient With Biclonal Gammopathy Using a Systemic Bortezomib-Based Regimen |
title_full | Case Report: Management of Primary Tracheobronchial Light Chain Amyloidosis in a Patient With Biclonal Gammopathy Using a Systemic Bortezomib-Based Regimen |
title_fullStr | Case Report: Management of Primary Tracheobronchial Light Chain Amyloidosis in a Patient With Biclonal Gammopathy Using a Systemic Bortezomib-Based Regimen |
title_full_unstemmed | Case Report: Management of Primary Tracheobronchial Light Chain Amyloidosis in a Patient With Biclonal Gammopathy Using a Systemic Bortezomib-Based Regimen |
title_short | Case Report: Management of Primary Tracheobronchial Light Chain Amyloidosis in a Patient With Biclonal Gammopathy Using a Systemic Bortezomib-Based Regimen |
title_sort | case report: management of primary tracheobronchial light chain amyloidosis in a patient with biclonal gammopathy using a systemic bortezomib-based regimen |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554224/ https://www.ncbi.nlm.nih.gov/pubmed/34722570 http://dx.doi.org/10.3389/fmed.2021.728561 |
work_keys_str_mv | AT yanwei casereportmanagementofprimarytracheobronchiallightchainamyloidosisinapatientwithbiclonalgammopathyusingasystemicbortezomibbasedregimen AT lipeng casereportmanagementofprimarytracheobronchiallightchainamyloidosisinapatientwithbiclonalgammopathyusingasystemicbortezomibbasedregimen AT wucen casereportmanagementofprimarytracheobronchiallightchainamyloidosisinapatientwithbiclonalgammopathyusingasystemicbortezomibbasedregimen AT zhouchuming casereportmanagementofprimarytracheobronchiallightchainamyloidosisinapatientwithbiclonalgammopathyusingasystemicbortezomibbasedregimen AT liaoaijun casereportmanagementofprimarytracheobronchiallightchainamyloidosisinapatientwithbiclonalgammopathyusingasystemicbortezomibbasedregimen AT yangwei casereportmanagementofprimarytracheobronchiallightchainamyloidosisinapatientwithbiclonalgammopathyusingasystemicbortezomibbasedregimen AT wanghuihan casereportmanagementofprimarytracheobronchiallightchainamyloidosisinapatientwithbiclonalgammopathyusingasystemicbortezomibbasedregimen |